Transdermal System Multi-Component Enhancer Vinpocetine Permeation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vinpocetine, a lipophilic and poorly water-soluble pharmaceutical active substance, has poor bioavailability and permeation through the skin due to its physicochemical properties, making transdermal administration challenging, and existing transdermal systems require large surface areas for therapeutic efficacy.
Innovation Solution
A transdermal therapeutic system using a multi-component enhancer system comprising terpenes, cyclic glucitol ethers, medium-chain triglycerides, and longer-chain alcohols to increase the permeation rate of vinpocetine, allowing for a smaller system size while achieving a therapeutically effective plasma level.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a matrix transdermal therapeutic system is used to administer vinpocetine, then the permeation rate increases, but the required surface area becomes too large (120 cm²) for patient acceptance
Solution Approach 1:
The patent changes the formulation parameters by introducing a multi-component enhancer system with specific components (terpenes, cyclic glucitol ethers, medium-chain triglycerides, and longer-chain alcohols) in optimized concentrations. This chemical parameter change enables achieving the required permeation rate with a much smaller surface area (40 cm² or less), resolving the contradiction between permeation efficacy and device size acceptability.
2Ease of operation
If vinpocetine is administered orally, then the administration is simple, but the bioavailability is very poor (6-7% in fasting state)
Solution Approach 1:
The patent uses the skin as an intermediary route of administration, bypassing the gastrointestinal tract and first-pass metabolism. The transdermal system with multi-component enhancers facilitates drug penetration through the skin barrier, providing an alternative pathway that maintains ease of administration while dramatically improving bioavailability to therapeutic levels.
3Reliability
If a liquid preparation with ethanol and 1-menthol is applied directly to skin, then the permeation rate increases to 6.45 μg/cm²×h, but the system requires repeated application and does not enable continuous release
Solution Approach 1:
The patent employs a composite formulation containing four different types of permeation enhancers (terpenes, cyclic glucitol ethers, medium-chain triglycerides, and longer-chain alcohols) working synergistically. This composite material system provides both high permeation rate and sustained continuous release over 24 hours or longer, eliminating the need for repeated applications while maintaining therapeutic plasma levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves a skin flux of 0.91 μg/cm2×h, enabling a daily dose of 2 mg of vinpocetine, sufficient to maintain a plasma level of 2 to 3 ng/ml, and can be applied over a 24-hour period with a surface area of 40 cm2 or less, improving patient acceptance and bioavailability.
Implementation Method 1
the partition coefficient log POctanol/Water of about 3.9 and the poor water-solubility of 0.02 μg/ml at room temperature characterise vinpocetine as a very lipophilic pharmaceutical active substance
Implementation Method 2
the absorption quota of vinpocetine in a fasting state is only about 6 to 7 percent
Data Source
AI summary
A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.